CAMBRIDGE, England and CAMBRIDGE, Mass. -- Acambis plc announces that it has entered into a collaboration with Cangene Corporation to develop a hyperimmune globulin for prevention and treatment of West Nile virus disease.
The agreement brings together the vaccine Acambis is developing against West Nile, ChimeriVax-West Nile, and Cangene's capability in the development and manufacture of hyperimmune products. Hyperimmune globulins are highly purified antibodies produced from human plasma. A hyperimmune globulin against West Nile can be used to treat people who have become infected with the virus and to give immediate protection to immunocompromised individuals, such as the elderly, whose immune systems may not be able to generate a sufficient immune response.
Acambis and Cangene will both participate in the development work for the West Nile hyperimmune globulin and share the costs of funding the project. Acambis will make available to Cangene its ChimeriVax-West Nile vaccine, which will be used to vaccinate Cangene's plasma donors to generate the hyperimmune globulin against West Nile virus.
West Nile virus is a flavivirus transmitted by mosquitoes. It was first identified in North America in 1999 when an outbreak in New York City and four states resulted in 62 cases and seven deaths. By the end of 2002, it had spread to a total of 44 states, resulting in 4,156 diagnosed cases and the death of 284 people. The first human cases were also identified in five Canadian provinces and the virus spread south into Mexico.
Acambis has developed its vaccine using its proprietary ChimeriVax technology and has recently filed an Investigational Drug Application with the Food and Drug Administration (FDA) to undertake a Phase I trial of its ChimeriVax-West Nile vaccine.
Dr John Brown, CEO of Acambis, said, "This collaboration is an ideal pairing of the West Nile vaccine that Acambis has developed with Cangene's technology and considerable expertise in the generation of hyperimmune products. This is an interesting opportunity to explore the potential for a product against West Nile that complements the vaccine we are currently developing and could enable us to provide protection for as wide a range of people as possible."
"West Nile spread across North America at an astonishing rate and has rapidly established itself as a public health concern," said Dr John Langstaff, president and CEO of Cangene. "With operations in Manitoba and Ontario, we are acutely aware of the threat of mosquito-borne infections and we believe that hyperimmune technology is well suited to meet the challenge."
Source: Acambis plc
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.